Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol
Diabetes therapy : research, treatment and education of diabetes and related disorders（2018）
摘要
In the original publication, the text in Table 2 stated ‘Hypersensitivity to the active substance, to Ferinject, or to any of its excipients’.
更多查看译文
关键词
Ferinject®,Ferric carboxymaltose,HbA1c,Intravenous,Iron deficiency,Type 2 diabetes mellitus
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要